IRIS
FERRERI, ANDRES JOSE MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.897
NA - Nord America 2.982
EU - Europa 2.113
SA - Sud America 1.920
AF - Africa 117
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.048
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.815
SG - Singapore 2.502
BR - Brasile 1.570
CN - Cina 1.433
HK - Hong Kong 931
SE - Svezia 626
VN - Vietnam 557
RU - Federazione Russa 341
IT - Italia 326
DE - Germania 231
GB - Regno Unito 144
AR - Argentina 137
FI - Finlandia 121
IN - India 83
EC - Ecuador 74
CA - Canada 73
ID - Indonesia 72
AT - Austria 69
MX - Messico 59
JP - Giappone 52
BD - Bangladesh 48
FR - Francia 46
ZA - Sudafrica 42
CO - Colombia 35
IE - Irlanda 34
NL - Olanda 32
PY - Paraguay 32
PL - Polonia 30
TR - Turchia 30
IQ - Iraq 29
ES - Italia 26
CL - Cile 25
UA - Ucraina 22
SA - Arabia Saudita 21
EG - Egitto 20
VE - Venezuela 20
MA - Marocco 17
PK - Pakistan 17
IR - Iran 16
PE - Perù 15
KE - Kenya 14
KR - Corea 14
PT - Portogallo 14
UZ - Uzbekistan 14
AU - Australia 13
LT - Lituania 8
TN - Tunisia 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
NP - Nepal 7
JM - Giamaica 6
AZ - Azerbaigian 5
CZ - Repubblica Ceca 5
GG - Guernsey 5
JO - Giordania 5
KZ - Kazakistan 5
LB - Libano 5
MY - Malesia 5
NO - Norvegia 5
OM - Oman 5
BO - Bolivia 4
BY - Bielorussia 4
CH - Svizzera 4
GT - Guatemala 4
KW - Kuwait 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
AL - Albania 3
BB - Barbados 3
BG - Bulgaria 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HN - Honduras 3
IL - Israele 3
LV - Lettonia 3
NG - Nigeria 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PA - Panama 3
PH - Filippine 3
PS - Palestinian Territory 3
RO - Romania 3
TW - Taiwan 3
BE - Belgio 2
CR - Costa Rica 2
ET - Etiopia 2
GE - Georgia 2
MM - Myanmar 2
RS - Serbia 2
SV - El Salvador 2
TH - Thailandia 2
YE - Yemen 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
EE - Estonia 1
EU - Europa 1
Totale 13.035
Salva come PNG Salva come JPEG
Città #
Singapore 1.086
Hong Kong 930
Dallas 850
Shanghai 370
Hefei 345
Ashburn 286
Lawrence 270
Princeton 270
Ho Chi Minh City 225
Beijing 151
São Paulo 130
Moscow 124
New York 123
Milan 98
Hanoi 92
Los Angeles 89
Helsinki 81
Nuremberg 72
Munich 52
Belo Horizonte 46
Rio de Janeiro 42
Guangzhou 37
Dublin 33
Tokyo 32
Boardman 31
Turku 30
Montreal 29
Vienna 29
Rome 27
Biên Hòa 26
Brasília 26
Chennai 25
Guayaquil 24
Johannesburg 24
Porto Alegre 24
Santa Clara 24
Poplar 23
Brooklyn 22
London 22
Warsaw 22
Asunción 21
Haiphong 21
Houston 21
Quito 21
Da Nang 20
Toronto 20
Denver 19
Hangzhou 18
Leicester 18
Sorocaba 18
Campinas 17
Jakarta 17
Osasco 17
Stockholm 17
Goiânia 16
Curitiba 15
Orem 15
The Dalles 15
Thái Bình 15
Boston 14
Mexico City 14
Mumbai 14
Phoenix 14
Chicago 13
Guarulhos 13
Nairobi 13
Salvador 13
San Francisco 13
Santiago 13
Shenzhen 13
Tashkent 13
Caxias do Sul 12
Columbus 12
Buenos Aires 11
Daejeon 11
Frankfurt am Main 11
Hải Dương 11
Manchester 11
Santo André 11
Seattle 11
Aracaju 10
Montes Claros 10
Ninh Bình 10
Taboão da Serra 10
Washington 10
Amsterdam 9
Ankara 9
Atlanta 9
Buccinasco 9
Falkenstein 9
Fremont 9
Lappeenranta 9
Lấp Vò 9
Naples 9
Novo Hamburgo 9
São Gonçalo 9
Baghdad 8
Bắc Giang 8
Cesano Boscone 8
Kassel 8
Totale 7.025
Salva come PNG Salva come JPEG
Nome #
Definition, diagnosis, and management of intravascular large B-Cell lymphoma: Proposals and perspectives from an international consensus meeting 281
Radiomics-Based Machine Learning Model for Predicting Overall and Progression-Free Survival in Rare Cancer: A Case Study for Primary CNS Lymphoma Patients 115
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome 111
A multicenter study of treatment of primary CNS lymphoma 106
Chronic lymphocytic leukaemia 103
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 99
ABS0671 IgG4-RELATED DISEASE IN OVERLAP WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: CLINICAL-PATHOLOGICAL CHARACTERISTICS AND THERAPEUTIC IMPLICATIONS OF AN ORPHAN DISEASE 95
A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL) 95
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review 88
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 84
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 82
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial 81
A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals 81
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 80
A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type 79
Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study). 79
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy 78
THREE-HOUR INFUSION OF METHOTREXATE AT 3 g/m2 SIGNIFICANTLY REDUCES CNS RELAPSES AND IMPROVES SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS AND INCREASED CNS RISK 78
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi 77
Chlamydia infection and lymphoma: Multiple detection methods highlight an association beyond lymphomas of the ocular adnexa 71
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: The TIER trial 70
A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27) 69
SHORT-TERM DOSE-DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV- AND HIV+ PATIENTS WITH BURKITT LYMHOMA 68
Activity of rituximab in extranodal marginal zone lymphomas (MALT-type). 67
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 67
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma 65
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma 64
Chronic lymphocytic leukemia 63
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 63
Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness 63
Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents 62
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 62
A retrospective series of upfront therapy in primary brain lymphomas 60
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study 59
The impact of histopathologic diagnosis on the proper management of testis neoplasms 58
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 58
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 58
Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center 58
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells 57
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 56
Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type 56
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 56
Primary central nervous system lymphoma 56
Cyclin D3 immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27(KIP1) IR prognostic role in primary gastric lymphomas (PGL). 55
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) 55
FEASIBILITY AND EFFICACY OF CHLAMYDIA PSITTACI ERADICATION WITH PROLONGED DOXYCYCLINE THERAPY IN LOCALIZED OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL): 7-YEAR RESULTS OF THE IELSG39 MULTICENTER TRIAL 54
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial 53
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis 52
Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma 52
Central nervous system marginal zone B-cell lymphoma associated with chlamydophila psittaci infection 52
New hopes in relapsed refractory primary central nervous system lymphoma 51
ORBIT IRRADIATION AS SALVAGE TREATMENT FOR PATIENTS WITH OCULAR ADNEXAL MALT LYMPHOMA (OAML) RELAPSED AFTER OR REFRACTORY TO CHLAMYDIA PSITTACI-ERADICATING ANTIBIOTIC THERAPY 50
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 50
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 50
Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods 50
Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma 49
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 49
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 49
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 49
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 48
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy 47
Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients (PTS) with primary CNS lymphoma (PCNSL) 47
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 45
Cyclin D3 (CyD3) immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27 IR prognostic role in primary gastric lymphomas (PGL) 45
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial 45
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms 44
Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa 44
Microvessel density is an independent predictor of survival in multiple myeloma patients. 44
Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP 44
Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas 44
Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae 43
Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients 43
Treatment of Ocular Adnexal Lymphoma with Intralesional Injection of Anti-CD20 Monoclonal Antibody: Preliminary Results 43
Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature 43
Gamma-delta t-cell lymphomas 42
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project 42
ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project 42
Prevention and management of secondary central nervous system lymphoma 42
Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis 42
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL) 42
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 41
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy 41
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 41
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions 41
Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL 41
Breaching the blood–brain tumor barrier for tumor therapy 41
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study 40
High-dose sequential chemoimmunotherapy supported by autologous stem cell transplantation in patients with systemic B-cell lymphoma and central nervous system involvement: interim analysis of a multicentre phase II Trial 40
Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-DoseCytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis 40
Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: A report from the International PTL Consortium 40
Le infezioni erpetiche nel paziente immunocompromesso 40
Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate 40
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group 39
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma 39
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential 39
Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial 39
MATILDE chemotherapy regimen for primary CNS lymphoma Results at a median follow-up of 12 years 39
Intraocular lymphoma (IOL): Treatment and outcome in HIV-patients. 39
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies 39
RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE (HD-MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (HD-ARAC) FOR PATIENTS WITH PRIMARY CNS LYMPHOMA (IELSG # 20 TRIAL): TOLERABILITY, ACTIVITY AND SURVIVAL ANALYSES 39
Totale 5.917
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.940
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.940
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 3 23 0 3 1 0 0
2021/2022232 0 0 2 71 9 6 16 91 4 5 1 27
2022/20231.341 631 271 56 6 9 135 42 86 53 10 17 25
2023/2024899 39 36 42 58 238 123 57 67 36 52 47 104
2024/20254.272 560 63 44 124 134 340 451 307 859 776 275 339
2025/20266.587 912 1.187 1.279 2.136 1.027 46 0 0 0 0 0 0
Totale 13.387